U.S.-Ready Leadership and Governance Structure to Support Global Expansion

CynosBio, Inc. (“CynosBio” or the “Company”), a regenerative medicine company developing autologous cell-based therapies in ophthalmology and orthopedics, today announced a strengthened leadership and governance structure designed to support the Company’s next phase of global expansion, including U.S. clinical development, strategic partnering, and international capital markets engagement.

The enhanced structure reflects CynosBio’s strategic transition from a Japan-validated regenerative medicine company into a globally scalable, U.S.-ready biotechnology platform company.

As the Company advances toward global Phase 3 development and future U.S. expansion, CynosBio believes that internationally experienced leadership, independent governance, and execution-oriented board oversight are critical to long-term value creation.

“CynosBio is entering a new phase where global execution capability and governance credibility are becoming as important as scientific innovation,” said Shinji Uga, President & CEO of CynosBio. “We are intentionally building a leadership and governance structure capable of supporting U.S. clinical development, global strategic partnerships, and international capital markets expectations.”

Board of Directors (Effective May 27, 2026)

President & CEO
Shinji Uga
Former CFO of CYBERDYNE Inc., where he led an award-winning IPO, global financing transactions, and strategic growth initiatives. Experienced in global financing, investor relations, and cross-border biotech strategy.

Independent Director (New)
Ken Takanashi
Vice Chairman, Shin Nippon Biomedical Laboratories, Ltd. (SNBL)
Widely recognized for supporting multiple Japan-origin biotech companies through U.S. Nasdaq listings, global partnerships, and international capital markets strategy, including Wave Life Sciences and Satsuma Pharmaceuticals.

Independent Director (New)
Yuichi Iwaki
President & CEO, MediciNova, Inc.
Physician-scientist and Nasdaq-listed biotech CEO with extensive experience in FDA strategy, orphan diseases, RMAT/ODD pathways, and U.S. capital markets.

Independent Director (Audit & Supervisory Committee Member) (New)
Shinobu Murakami
Former pharmaceutical and regenerative medicine business executive with extensive cross-border business development, alliance management, and operational leadership experience.

Independent Director (Audit & Supervisory Committee Member)
Kentaro Motoki
Attorney-at-Law and CPA
AGRI Law & Accounting Office

Independent Director (Audit & Supervisory Committee Member)
Tsuneo Shimoda
Independent Director (Audit & Supervisory Committee Member), JMDC Inc.
Former Head of Legal Affairs with extensive public-company governance and compliance experience.

Executive Leadership Team

President & CEO
Shinji Uga — Corporate Management, Global Strategy, Financing & Investor Relations

Executive Officer, CFO
Kosuke Ota — Finance & Corporate Strategy
Former investment banker with more than 100 M&A and financing advisory transactions.

Executive Officer, CCO
Tomohiro Maruyama — Commercial & Marketing
Former senior marketing leader at Bristol Myers Squibb with extensive launch and commercialization experience across hepatology and oncology products in Japan.

Executive Officer, CDO (New)
Hiroyuki Hosokawa — Regulatory Affairs & Clinical Development
Global clinical development leader with extensive experience in orthopedic development, FDA strategy, and international Phase 1–3 trial execution, including U.S. regulatory interactions.

Governance Designed for Global Execution

CynosBio believes robust governance is essential as the Company advances toward global clinical development and deepens engagement with U.S. investors, strategic partners, and international stakeholders.

The Company is strengthening its governance framework to support:
• independent and globally experienced oversight
• strategic decision-making aligned with U.S. expansion
• long-term shareholder value creation
• future U.S.-based operational and financing structures

CynosBio is also supported by a U.S. advisory network with expertise spanning FDA strategy, ophthalmology commercialization, strategic M&A, and U.S. capital markets.

About CynosBio

CynosBio is a regenerative medicine company developing autologous cell-based therapies in ophthalmology and orthopedics.

The Company’s lead programs include:
• Sakracy® — a Japan-approved ocular surface regeneration therapy preparing for global Phase 3 development
• IK-01 — a cartilage regeneration therapy supported by Japan Phase 3 structural efficacy data including MRI, arthroscopy, and biopsy findings

CynosBio aims to become a globally scalable specialty regenerative medicine company focused on severe unmet medical needs.